What is Bristol-Myers Squibb's short-term borrowings?

Bristol-Myers Squibb (BMY) reported short-term borrowings of $2.31B in Q1 2026.

How has Bristol-Myers Squibb's short-term borrowings changed year-over-year?

Bristol-Myers Squibb's short-term borrowings decreased by 35.1% year-over-year, from $3.55B to $2.31B.

What is the long-term trend for Bristol-Myers Squibb's short-term borrowings?

Over 5 years (2020 to 2025), Bristol-Myers Squibb's short-term borrowings has grown at a -0.7% compound annual growth rate (CAGR), from $2.34B to $2.26B.

What does short-term borrowings mean?

Debt that the company must pay back within one year.

Current Liabilities

Short-Term Borrowings

Bristol-Myers Squibb Short-Term Borrowings increased by 2.1% to $2.31B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 35.1%, from $3.55B to $2.31B. Over 5 years (FY 2020 to FY 2025), Short-Term Borrowings shows relatively stable performance with a -0.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionCurrent Liabilities

CategoryLiquidity

SignalLower is better

VolatilityModerate

First reportedQ4 2014

Last reportedQ1 2026Apr 30, 2026

How to read this metric

Higher levels may signal liquidity pressure or aggressive working capital management, while lower levels suggest a stronger cash position.

Detailed definition

This represents the company's debt obligations that are due for repayment within one fiscal year, excluding the current...

Peer comparison

Varies significantly by industry; pharmaceutical companies typically maintain manageable levels to support R&D cycles.

Metric ID: short_term_borrowings

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$2.66B	$5.07B	$4.95B	$7.52B	$4.95B	$2.13B	$4.26B	$2.75B	$3.02B	$5.47B	$3.12B	$6.19B	$3.53B	$1.08B	$2.05B	$3.55B	$4.72B	$4.51B	$2.26B	$2.31B
QoQ Change	—	+90.8%	-2.3%	+52.0%	-34.2%	-57.0%	+100.0%	-35.5%	+9.7%	+81.0%	-42.9%	+98.5%	-43.0%	-69.5%	+89.8%	+73.7%	+32.7%	-4.4%	-49.9%	+2.1%
YoY Change	—	—	—	—	+86.6%	-57.9%	-13.8%	-63.4%	-39.0%	+156.4%	-26.9%	+124.9%	+16.9%	-80.3%	-34.4%	-42.6%	+33.5%	+318.3%	+10.5%	-35.1%

Range$1.08B – $7.52B

CAGR-2.9%

Avg YoY Growth+22.1%

Median YoY Growth-20.3%

Short-Term Borrowings at Other Companies

Johnson & JohnsonJNJ View metric

AbbVieABBV View metric

Frequently Asked Questions

What is Bristol-Myers Squibb's short-term borrowings?: Bristol-Myers Squibb (BMY) reported short-term borrowings of $2.31B in Q1 2026.
How has Bristol-Myers Squibb's short-term borrowings changed year-over-year?: Bristol-Myers Squibb's short-term borrowings decreased by 35.1% year-over-year, from $3.55B to $2.31B.
What is the long-term trend for Bristol-Myers Squibb's short-term borrowings?: Over 5 years (2020 to 2025), Bristol-Myers Squibb's short-term borrowings has grown at a -0.7% compound annual growth rate (CAGR), from $2.34B to $2.26B.
What does short-term borrowings mean?: Debt that the company must pay back within one year.